Related Experiment Video
Updated: Nov 28, 2025

Electrophysiological Measurements and Analysis of Nociception in Human Infants
Published on: December 20, 2011
Neuropathic pain in children: Steps towards improved recognition and management
1Developmental Neurosciences Program, UCL Great Ormond St Institute of Child Health, London, United Kingdom; Department of Anaesthesia and Pain Medicine, Great Ormond St Hospital NHS Foundation Trust, London, United Kingdom.
Insights
Diagnosing neuropathic pain in children is challenging due to age-related factors and the need for validated tools. Advanced methods like sensory testing, brain imaging, and genetic analysis can improve individualized treatment and clinical trials for pediatric neuropathic pain.
Area of Science:
- Pediatric neurology
- Pain medicine
- Neuroscience
Background:
- Neuropathic pain in children presents significant challenges in recognition, management, and leads to substantial pain-related disability.
- Current diagnostic methods, including clinical history and screening tools, face limitations in young children and require further validation in older age groups.
- Age- and sex-dependent physiological changes can impact the feasibility and interpretation of confirmatory tests for somatosensory nervous system lesions.
Purpose of the Study:
- To explore advanced diagnostic and research methodologies for neuropathic pain in children.
- To identify potential biomarkers and genetic causes of pediatric neuropathic pain.
- To inform individualized therapy and clinical trial stratification for improved management.
Main Methods:
- Quantitative sensory testing (QST) to identify mechanism-related sensory profiles.
- Brain imaging as a potential biomarker for central pain processing alterations.
- Genetic analysis to uncover known and novel causes of neuropathic pain.
- Utilizing patient- and parent-reported outcome measures.
Main Results:
- Quantitative sensory testing can delineate specific sensory profiles related to pain mechanisms.
- Brain imaging shows potential as a biomarker for altered central pain processing and modulation.
- Genetic analysis offers insights into the underlying causes of neuropathic pain.
- Existing outcome measures, alongside new research methodologies, are crucial.
Conclusions:
- Developing validated, mechanism-based standardized endpoints is essential for advancing the evidence-based management of pediatric neuropathic pain.
- Individualized therapy and clinical trial stratification can be improved through advanced research methodologies and validated endpoints.
- Further research into QST, neuroimaging, and genetics will enhance diagnostic accuracy and treatment strategies for children with neuropathic pain.
Abstract:
Neuropathic pain in children can be severe and persistent, difficult to recognise and manage, and associated with significant pain-related disability. Recognition based on clinical history and sensory descriptors is challenging in young children, and screening tools require further validation at older ages. Confirmatory tests can identify the disease or lesion of the somatosensory nervous system resulting in neuropathic pain, but feasibility and interpretation may be influenced by age- and sex-dependent changes throughout development. Quantitative sensory testing identifies specific mechanism-related sensory profiles; brain imaging is a potential biomarker of alterations in central processing and modulation of both sensory and affective components of pain; and genetic analysis can reveal known and new causes of neuropathic pain. Alongside existing patient- and parent-reported outcome measures, somatosensory system research methodologies and validation of mechanism-based standardised end-points may inform individualised therapy and stratification for clinical trials that will improve evidence-based management of neuropathic pain in children.
Related Concept Videos
Analgesia and Pain Management
Nociception
Pain

